John Parkinson

The strategies address booster doses, travel, and rapid response.

The first Omicron COVID-19 case was discovered in California. The patient, who traveled from South Africa, has since recovered.

As there is a lot of information regarding the Omicron variant, here is our latest slideshow to offer some insights on it.

Moderna and Pfizer's CEOs voice doubt on the current vaccines’ efficacy with the new variant, but are developing prophylaxis vaccines and treatment strategies to curtail the new strain.

The strain identified as B.1.1.529 is causing some travel restrictions from some African countries, and medical science is rushing to understand its potential impact on the global stage.

HIV Stakeholders weigh on the future of PrEP.

The federal agency's decision makes this the first CMV treatment for this patient population.

This infection has the ability to remain undetected and the potential to spread very quickly in long-term care facilities and hospitals.

As providers were challenged to care for patients with severe COVID-19 In the first year of the pandemic, antibiotic usage increased. Listen to clinicians talk about this specific challenge and how prescribing practices evolved over time.

From its origins as a serendipitous discovery to being successfully prescribed for nearly a century, antibiotics remain a foundation of medicine. However it has major ongoing challenges including the rise of superbugs and the development of antimicrobial resistance (AMR). There are some prospective strategies to combat AMR on the horizon.

Providers and key stakeholders weigh in on this significant topic.

CEO Christopher Burns spoke about their investigational therapy pipeline, the long view perspective for the company, and how the federal government’s use of the nomenclature innovation might actually hinder incremental improvements in antibiotic development.

This agreement with the Medicines Patient Pool (MPP) would allow licensing of the company’s antiviral treatment candidate, PF-07321332, internationally to numerous countries.

How 1 provider is training medical peers to offer PrEP education and prescribe it.

Fenway Health’s Pride in Our Health podcast is an example of new voices being heard, and an alternative means of getting health information to the general public.

Clinical care is evolving in this area and shows promise in the various modalities and therapies that are going through clinical trials.

During the C Diff Foundation's Annual conference, providers and stakeholders offered insights on the latest investigational therapies and modalities as they advance through clinical trials.

Results on this investigational antibiotic in its phase 2A study were presented at the C Diff. Conference today.

At the C Diff Foundation Conference, promising investigational modalities and therapies, as well as better treatment approaches are all being discussed in hopes of some real inroads being made in this field in the near future.

Although no longer indicated as a first-line therapy, metronidazole still has therapeutic benefits and can serve patients in certain settings and circumstances.

Highlights from the morning session of the C Diff Foundation Conference included data about Pfizer's investigational vaccine, insights about Seres Therapeutics microbiome therapeutic, and a look at CDI incidence rates around COVID-19.

The development of these programs are being looked at for private practices in the community settings to try to create better prescribing practices and avoid the potential progression to health care associated infections.

Loma Linda University worked with local leaders to help promote equitable delivery of COVID-19 vaccines in Black communities.

The emergency use authorization (EUA) is based on the vaccine data and the Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommendation.

This recommendation was based off of data showing the vaccine was 90% efficacious in this population, and sets the stage for the first COVID-19 vaccine in the age group.

The committee is meeting today to review the data presented to them, and will vote to either recommend or not an Emergency Use Authorization in this pediatric population.

The White House said it has secured enough of the Pfizer-BioNTech vaccine supply to offer vaccinations for everyone in this age group.

The company’s current investigational medical device, Sigyn Therapy, is a novel medical device that is being studied for addressing viral pathogens and bacterial toxins to avoid this massive inflammation onslaught and the potential of sepsis.

Merck recently announced results looking at their islatravir implant studied for HIV prevention for 3 months. The long-term goal is to have the implant last 12 months following administration.

This promising class of therapy is an expanding treatment option for people who are looking for HIV prevention offerings.